Physician profile
Janice E Baker
NPI 1265642953
$4,424.33
in general payments reported to CMS, 2019-2025
33 companies · $21.72 in 2025
The $21.72 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,323 · 2022: $1,622 · 2023: $318 · 2024: $140 · 2025: $21.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $479.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $426.79 | 2021-2022 | |
| Ucb, INC. | $367.41 | 2021-2024 | Briviact |
| Allergan, INC. | $305.93 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $300.46 | 2021-2024 | Andexxa |
| Abbvie INC. | $290.21 | 2021-2023 | |
| Celgene Corporation | $273.75 | 2021-2022 | |
| Eisai INC. | $203.37 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $191.34 | 2021-2022 | |
| Emd Serono, INC. | $186.22 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $164.17 | 2021-2023 | Ponvory |
| Biohaven Pharmaceuticals, INC. | $162.24 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $155.26 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $138.95 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $137.55 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $130.27 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $128.98 | 2021-2022 | |
| Chiesi USA, INC. | $116.53 | 2023 | Cleviprex |
| Amgen INC. | $104.84 | 2021-2022 | |
| Boston Scientific Corporation | $91.92 | 2022 | |
| Alexion Pharmaceuticals, INC. | $80.93 | 2021 | |
| Pfizer INC. | $75.83 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $70.28 | 2022 | |
| Kyowa Kirin, INC. | $58.15 | 2021-2022 | |
| Lilly USA, LLC | $47.35 | 2022 | |
| Neurelis, INC. | $43.12 | 2021-2022 | |
| Insightec,INC | $30.52 | 2022 | |
| Genentech USA, INC. | $27.91 | 2021-2022 | |
| Lundbeck LLC | $24.76 | 2021-2022 | |
| Catalyst Pharmaceuticals, INC. | $24.18 | 2022 | |
| Adamas Pharmaceuticals, INC. | $20.60 | 2021 | |
| Sunovion Pharmaceuticals INC. | $17.47 | 2022 | |
| Amneal Pharmaceuticals LLC | $14.76 | 2022 | |
| Arbor Pharmaceuticals, INC. | $12.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janice Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.